53329 Long-Term Adverse Event Risks of Systemic Janus Kinase (JAK) Inhibitors versus Traditional Immunomodulators
Recommended Citation
Lamberg O, Pandher K, Lim H. 53329 Long-Term Adverse Event Risks of Systemic Janus Kinase (JAK) Inhibitors versus Traditional Immunomodulators. J Am Acad Dermatol 2024; 91(3):AB1.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: Systemic Janus kinase (JAK) inhibitors have exhibited treatment efficacy in managing dermatologic conditions characterized by excessive inflammation and immune dysregulation.1,2 While currently approved for the treatment of atopic dermatitis and alopecia areata, their broader potential, including off-label use and ongoing clinical trials for other dermatologic conditions, has generated considerable interest. Despite their efficacy, concerns have arisen due to the additional black box warning labels issued by the US Food and Drug Administration regarding long term adverse events associated with systemic JAK inhibitors.3 Methods: We conducted a comprehensive literature review to assess the long-term adverse events associated with oral JAK inhibitors in comparison to traditional immunomodulators. Our search focused on articles reporting medication exposure exceeding one year and subsequent adverse event development. We collected data on adverse event rates including malignancies (excluding non-melanoma skin cancer (NMSC)), NMSC, major adverse cardiovascular events (MACE), venous thromboembolism (VTE), infections, and other outcomes. Our evaluation encompassed several JAK inhibitors commonly used for dermatologic conditions, such as tofacitinib, baricitinib, upadacitinib, ruxolitinib, as well as traditional immunomodulators, including cyclosporine, methotrexate, etanercept, adalimumab, and systemic steroids. Results: Our analysis revealed equivalent or lower incidence rates per 100 patient-years for major adverse events including malignancy (excluding NMSC), NMSC, MACE, VTE, and infections when comparing JAK inhibitors to the majority of conventional immunomodulators. Conclusion: These findings provide valuable insights into the safety profile of JAK inhibitors and have significant implications for guiding the management of dermatologic conditions that necessitate the use of JAK inhibitors or traditional immunomodulators.
Volume
91
Issue
3
First Page
AB1
